PaCaReg: A Multicenter Registry Trial for the Assessment of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma

What this Trial Is About

Researchers are conducting a multicenter registry trial called PaCaReg to study pancreatic ductal adenocarcinoma, a type of pancreas cancer. The trial aims to understand clinical, epidemiological, and biological profiles in patients with this condition. The study is observational and focuses on collecting data to assess various aspects related to the disease and its treatment. Participants in this study are those diagnosed with pancreatic ductal adenocarcinoma or those with a highly suspicious diagnosis prior to curative surgery. The trial does not involve experimental treatments but gathers information on the therapies patients receive and their outcomes. Data collection spans from the time of diagnosis through up to five years after curative resection, covering therapy modalities, quality of life, tumor surveillance, and predictive markers. During the study, participants' medical information, treatment details, and quality of life will be monitored over time. The researchers will assess outcomes such as survival, therapy effects, and epidemiological factors. This long-term observation helps in understanding the disease better and may guide future care strategies. Participation involves providing informed consent and allowing access to clinical data during the observation period.

PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma